biostudies-literatureUnknown23(1)Gantenbein ARNovartis Pharma Schweiz AG<h4>Background</h4>The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.<h4>Methods</h4>An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months.<h4>Results</h4>In total, 172 adults with chronic or episodic migraThe journal of headache and pain142https://www.ebi.ac.uk/biostudies/studies/S-EPMC9673191biostudies-literatureSwiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.PMC9673191Ryvlin PArzt MEMeyer IPetersen JAGantenbein ARLandmann GViceic DSchafer EAgosti RZecca CSchankin CJPohl HKamm CPMeier NMerki-Feld GSfalseSwiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.<h4>Background</h4>The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.<h4>Methods</h4>An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months.<h4>Results</h4>In total, 172 adults with chronic or episodic migra2022-01-01T00:00:00Z2022 Nov2025-04-04T08:08:51.021Z2025-02-19T01:56:44.01ZS-EPMC96731913640117210.1186/s10194-022-01515-8